Novartis wins approval for first malaria drug for newborns
FT.com
Swiss pharma group says lack of provision for small infants has led to ‘treatment gap’ in deadly disease
Swiss pharma group says lack of provision for small infants has led to ‘treatment gap’ in deadly disease
Get ready for a sneak peek that’s as impactful as it is inspiring! Novartis is making its Super Bowl debut with a game-changing..
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019